我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

非诺贝特对糜酶诱导的大鼠心脏成纤维细胞增殖及胶原合成的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第5期
页码:
629-633
栏目:
基础研究
出版日期:
2009-07-14

文章信息/Info

Title:
Effect of fenofibrate on chymase-induced proliferation and collagen synthesis of rat cardiac fibroblast
作者:
王晓武; 袁彬彬; 张卫达; 罗林; 梅汝刚; 王晓莉; 李杰
广州军区广州总医院心脏外科中心，广东 广州 510010
Author(s):
WANG Xiao-wu;  YUAN Bin-bin;  ZHANG Wei-da;  LUO Lin;  MEI Ru-gang;  WANG Xiao-li;  LI Jie
Centre of Cardiac Surgery, Guangzhou General Hospital, Guangzhou Military Area Command, Guangzhou 510010, Guangdong, China
关键词:
心肌纤维化; 非诺贝特; 糜酶; 心脏成纤维细胞; 胶原; 大鼠
Keywords:
myocardial fibrosis;  fenofibrate;  chymase;  cardiac fibroblast;  collagen
分类号:
R972.6
DOI:
-
文献标识码:
A
摘要:
目的: 探讨过氧化物酶增殖物激活受体α(PPARα)激动剂非诺贝特对心脏肥大细胞糜酶诱导的心脏成纤维细胞增殖及胶原合成的影响。方法: 分离、培养新生SD大鼠心脏的成纤维细胞，采用MTT比色法(A490值)测定细胞数目。用流式细胞仪分析细胞周期。用3H-脯氨酸掺人法测定总胶原合成，实时定量PCR检测I型和Ⅲ型胶原mRNA的表达。结果: MTT比色法的结果显示，与正常对照相比，糜酶作用后A490值升高为0.42±0.05，而给予不同浓度的非诺贝特后，A490值降低为0.35±0.06（50 mg/L）及0.28±0.05（100 mg/L），明显低于单纯糜酶组(P<0.05)。3H-脯氨酸掺入法的结果显示，与正常对照组相比，糜酶作用24 h后，心脏成纤维细胞3H-脯氨酸掺入量升高为789±67；而给予糜酶+非诺贝特后，3H-脯氨酸掺入量明显低于单纯糜酶组(P<0.05)。PCR的结果显示，与正常对照组相比，糜酶作用24 h后，心脏成纤维细胞中Ⅰ、Ⅲ型胶原mRNA表达的水平显著升高(P<0.05)；而给予糜酶+非诺贝特后，两型胶原mRNA的表达明显低于单纯糜酶组(P<0.05)。流式细胞仪分析的结果显示，单纯糜酶处理后，S期细胞的百分率和细胞的增殖指数明显增加；而非诺贝特则能显著抑制这些改变。结论: PPARα激动剂非诺贝特能够抑制糜酶诱导的心肌纤维化，可能是今后逆转心肌纤维化的另一个有效途径。
Abstract:
AIM: To investigate the effect of fenofibrate on chymase-induced proliferation and collagen synthesis of rat cardiac fibroblasts (CFs). METHODS: Cultured CFs from neonatal Sprague Dawley rats were isolated and treated with chymase or together with fenofibrate. Cellular number and cycle were evaluated by MTT colorimetry (A490 value) and flow cytometry. The total collagen synthesis by CFs was examined by 3H-proline incorporation, and the expressions of mRNAs of types I and III collagen in CFs were determined by real-time PCR. RESULTS: MTT colorimetry showed that compared with those in control group, A490 increased to 0.42±0.05, whereas the value decreased to 0.35±0.06 (50 mg/L) and 0.28±0.05 (100 mg/L) in fenofibrate+cytometry group (P<0.05). The 3H-proline incorporations increased to 789±67 after chymase treatment; however, it significantly decreased with fenofibrate (P<0.05). Real-time PCR showed that mRNA levels of types I and III collagen in CFs were markedly upregulated by chymase (P<0.05), but fenofibrate inhibited the upregulation (P<0.05). Cellular cycle analysis showed that chymase markedly decreased cellular percentage in G0/G1 stage and increased cellular percentage in S stage and proliferation index (PI), which were significantly attenuated by fenofibrate (P<0.05). CONCLUSION: PPARα agonist fenofibrate inhibits chymase-induced proliferation and collagen synthesis of rat CFs, which is probably a potential way to attenuate myocardial fibrosis.

参考文献/References

［1］ Caglayan E, Stauber B, Collins AR, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis［J］. Diabetes, 2008, 57(9):2470-2479.

［2］ Kobayashi N, Ohno T, Yoshida K, et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats［J］. Am J Hypertens, 2008, 21(5):576-581.

［3］ Fujita K, Maeda N, Sonoda M, et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha［J］. Arterioscler Thromb Vasc Biol, 2008, 28(5):863-870.

［4］ Hao GH, Niu XL, Gao DF, et al. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts［J］. Br J Pharmacol, 2008, 153(7):1409-1419.

［5］ Smeets PJ, Teunissen BE, Willemsen PH, et al. Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload［J］. Cardiovasc Res, 2008, 78(1):79-89.

［6］ Nakamura T, Yamamoto E, Kataoka K, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan［J］. Hypertension, 2008, 51(2):296-301.

［7］ Henderson BC, Sen U, Reynolds C, et al. Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone［J］. Int J Biol Sci, 2007, 3(6):385-392.

［8］ Lebrasseur NK, Duhaney TA, De Silva DS, et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension［J］. Hypertension, 2007, 50(3):489-496.

［9］ Teunissen BE, Smeets PJ, Willemsen PH, et al. Activation of PPAR delta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts［J］. Cardiovasc Res, 2007, 75(3):519-529.

备注/Memo

备注/Memo:
收稿日期：2009-3-31.资助项目：广东省自然科学基金项目编号（8151001002000025） 通讯作者：张卫达，主任医师，主要从事先天性心脏病、冠心病和心脏移植等外科治疗研究Email: zhoujun923@163.com 作者简介：王晓武，副主任医师，博士Email: xzwk_wxw@hotmail.com
更新日期/Last Update: 2009-07-22